Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QTI571 · 1 trial · 1 indication
All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects.
| Arm | Type | Description |
|---|---|---|
| QTI571 | EXPERIMENTAL | Participants will receive QTI571 during 3 years. |
| Name | Type | Description |
|---|---|---|
| QTI571 | DRUG | QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day. |
Inclusion Criteria: * patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH) and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in Japan. * Patient is currently benifitting form the treatment with QTI571 in the opinion of the investigator. Exc...
QTI571 is an investigational small molecule being developed for severe pulmonary arterial hypertension, a condition of high blood pressure in the arteries of the lungs. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
QTI571 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with severe pulmonary arterial hypertension.
QTI571 is in Phase 3 clinical development for severe pulmonary arterial hypertension. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its potential as a treatment for this condition.
QTI571 has been studied in a completed Phase 3 clinical trial registered as NCT02042014. This open-label, multi-center study was designed to provide QTI571 to patients with severe pulmonary arterial hypertension in Japan who had participated in a prior extension study. The trial enrolled 8 participants.
QTI571 is the investigational name for this drug candidate developed by Novartis. No alternative names have been reported in the available clinical trial information, and it is identified solely by the designation QTI571 in the context of its development for severe pulmonary arterial hypertension.